{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T11:12:20Z","timestamp":1773486740738,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11899-018-0465-7","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T05:06:38Z","timestamp":1533013598000},"page":"341-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia"],"prefix":"10.1007","volume":"13","author":[{"given":"Aziz","family":"Nazha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"issue":"6","key":"465_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ajh.24396","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol. 2016;91(6):631\u201342.","journal-title":"Am J Hematol"},{"issue":"5","key":"465_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.23962","volume":"90","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90(5):411\u20136.","journal-title":"Am J Hematol"},{"issue":"3","key":"465_CR3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V63.3.634.634","volume":"63","author":"P Solal-Celigny","year":"1984","unstructured":"Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, et al. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood. 1984;63(3):634\u20138.","journal-title":"Blood"},{"issue":"7","key":"465_CR4","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292\u2013302.","journal-title":"Blood"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1038\/bcj.2016.5","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e393.","journal-title":"Blood Cancer J"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1038\/bcj.2015.113","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.","journal-title":"Blood Cancer J"},{"issue":"10","key":"465_CR7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"19","key":"465_CR8","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"11","key":"465_CR9","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206\u201312.","journal-title":"Leukemia"},{"issue":"4","key":"465_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","volume":"87","author":"JM Bennett","year":"1994","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87(4):746\u201354.","journal-title":"Br J Haematol"},{"issue":"20","key":"465_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"11","key":"465_CR12","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/leu.2016.138","volume":"30","author":"A Nazha","year":"2016","unstructured":"Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30(11):2214\u201320.","journal-title":"Leukemia"},{"issue":"12","key":"465_CR13","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1038\/leu.2017.266","volume":"31","author":"A Nazha","year":"2017","unstructured":"\u2022\u2022 Nazha A, Al-Issa K, Hamilton BK, et al. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017;31(12):2848\u201350. This is the first study to incorporate molecular data into four commonly used prognostic models in MDS and CMML.","journal-title":"Leukemia"},{"issue":"1","key":"465_CR14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","volume":"74","author":"GF Sanz","year":"1989","unstructured":"Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74(1):395\u2013408.","journal-title":"Blood"},{"issue":"1","key":"465_CR15","first-page":"52","volume":"6","author":"C Aul","year":"1992","unstructured":"Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6(1):52\u20139.","journal-title":"Leukemia"},{"issue":"9","key":"465_CR16","first-page":"1315","volume":"7","author":"P Morel","year":"1993","unstructured":"Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7(9):1315\u201323.","journal-title":"Leukemia"},{"issue":"6","key":"465_CR17","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079\u201388.","journal-title":"Blood"},{"key":"465_CR18","doi-asserted-by":"crossref","unstructured":"Nazha A, Seastone D, Keng M, et al. The revised international prognostic scoring system (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leuk Lymphoma. 2015:1\u201312.","DOI":"10.3109\/10428194.2015.1041391"},{"issue":"6","key":"465_CR19","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.3324\/haematol.2015.140962","volume":"101","author":"A Nazha","year":"2016","unstructured":"Nazha A, Komrokji RS, Garcia-Manero G, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016;101(6):e224\u20137.","journal-title":"Haematologica"},{"issue":"6","key":"465_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/cncr.23697","volume":"113","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351\u201361.","journal-title":"Cancer"},{"issue":"12","key":"465_CR21","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood"},{"issue":"12","key":"465_CR22","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.3109\/10428194.2015.1041391","volume":"56","author":"A Nazha","year":"2015","unstructured":"Nazha A, Seastone DP, Keng M, Hobson S, Kalaycio M, Maciejewski JP, et al. The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leuk Lymphoma. 2015;56(12):3437\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"465_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"2","key":"465_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","volume":"100","author":"U Germing","year":"2002","unstructured":"Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731\u20132. author reply 2-3","journal-title":"Blood"},{"issue":"6","key":"465_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/10428190701216386","volume":"48","author":"M Beran","year":"2007","unstructured":"Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007;48(6):1150\u201360.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"465_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383.","journal-title":"Haematologica"},{"issue":"15","key":"465_CR27","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"key":"465_CR28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504\u201310.","journal-title":"Leukemia"},{"issue":"12","key":"465_CR29","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/leu.2017.164","volume":"31","author":"BJ Patel","year":"2017","unstructured":"Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, et al. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017;31(12):2815\u201323.","journal-title":"Leukemia"},{"issue":"12","key":"465_CR30","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","volume":"121","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121(12):2186\u201398.","journal-title":"Blood"},{"key":"465_CR31","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1038\/bcj.2016.5","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"\u2022\u2022 Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e393. Important study that characterizes the clinical and molecular landscapes in CMML.","journal-title":"Blood Cancer J"},{"issue":"7","key":"465_CR32","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"\u2022 Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7):e333. This study evaluated the prognostic impact of estachlised models in a large international cohort of CMML patients from seven US and European centers.","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"465_CR33","first-page":"4255","volume":"130","author":"A Nazha","year":"2017","unstructured":"Nazha A, Patnaik MM, Komrokji RS, et al. Model heterogeneity in predicting outcomes in patients with chronic myelomonocytic leukemia (CMML): an overestimation of survival in lower-risk group. Blood. 2017;130(Suppl 1):4255.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-018-0465-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T14:45:39Z","timestamp":1571669139000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-018-0465-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s11899-018-0465-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"31 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}